CSL has received approval from the European Commission (EC) for Andembry (garadacimab) to prevent recurrent attacks of ...
The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback